ModerateVitamin K antagonist anticoagulants×Xanthine oxidase inhibitors
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs, both the originator and the generic, list allopurinol among the drugs that can potentiate its anticoagulant effect (AEMPS). According to the Spanish allopurinol SmPC, isolated cases of an increased anticoagulant effect of warfarin and other coumarins have been reported with allopurinol. The SmPC does not explain how this happens (allopurinol SmPC, AEMPS). The documents give data only for other anticoagulants. According to the US label, allopurinol prolongs the half-life of dicoumarol by an unknown mechanism. It may also inhibit the metabolism of warfarin and so potentiate its effect (allopurinol prescribing information, US Food and Drug Administration, FDA).
Symptoms
The main risk is bleeding from an increased effect of acenocoumarol. Cases of an increased anticoagulant effect have been reported when allopurinol was given with coumarins (allopurinol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With warfarin, allopurinol may increase the anticoagulant effect, so monitor patients for excessive anticoagulation (allopurinol prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. According to the Spanish allopurinol SmPC, all patients on anticoagulants should be monitored carefully (allopurinol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when allopurinol is added and when it is stopped (acenocoumarol SmPCs, AEMPS). When allopurinol is added to warfarin or dicoumarol, the US allopurinol label says to monitor for excessive anticoagulation, check the international normalised ratio (INR) or prothrombin time frequently and adjust the anticoagulant dose. It does not mention acenocoumarol (allopurinol prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Allopurinol tablet (Dr. Reddy's Laboratories Limited) – Prescribing Information (2018)– ; DailyMed setid 19a138b8-d225-03e6-f762-abe71560204b
- AEMPS: Ficha técnica Zyloric 100 mg (alopurinol) (2026)– AEMPS CIMA, Zyloric 100 mg comprimidos, nº registro 43775, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2